4 Fallen Angels on ASX you need to look at now!
Marc Kennis, April 14, 2023
Our own Stuart Roberts shares his insights on 4 “Fallen Angel” stocks on AusBiz.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
4 Fallen Angels on ASX
Stuart suggests that Domino’s (ASX:DMP) serves as an advanced recession indicator, demonstrating strong growth potential as it continually expands its international store count. Although rising mozzarella prices raise concerns, Stuart views this as a temporary setback, with the stock likely to rebound.
Stuart also emphasizes Kogan.com (ASX:KGN) as the “Everything store” for the Southern hemisphere, indicating that both Kogan and its competitors, such as Amazon, have room to grow as logistics infrastructure improves.
In reference to Xero (ASX:XRO), Stuart regards it as the top accounting software for small and medium-sized enterprises, advised by accountants. The company perpetually expands globally and appears expensive due to the market capitalising on its future growth potential.
Wrapping up our Fallen Angels on ASX, Stuart talks about LendLease (ASX:LLC), renowned for multi-year developments, like Barangaroo in Sydney. He asserts that the company possesses a world-leading franchise that the market struggles to properly capitalise on. As COVID-19 and inflation wane, Stuart envisions LendLease’s stock potentially returning to previous levels.
Watch the full interview here!
Stuart Roberts talks about 4 Fallen Angels on ASX
Need solid trading and investment ideas on ASX?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…
Here’s how tariffs impact the stock market and its investors
Many would be wondering how tariffs impact the stock market and its investors. On ‘Liberation Day‘, the returned President Trump…
What are the oldest companies on the ASX? Here are 5 of them and the secrets to their success!
In this article, we look at 5 of the oldest companies on the ASX. Now, we are not claiming these…